🟢 Moleculin Biotech is trading 6.2% up today after Mexico grants patent for lung-targeted Annamycin technology

Moleculin Biotech is trading up 6.2% now at $0.60 after Mexico granted a patent protecting its lung-targeted liposomal Annamycin technology.

• Announced September 23, 2026, Patent No. 436849 protects the technology through November 23, 2040.
• The patent strengthens the company’s international intellectual-property portfolio and supports Annamycin’s longer-term commercialization potential.
• Shares fell 32.71% on September 21, then rebounded 8.61% on September 22.